Faculty Bios top

Paul Bunn, Jr., MD
Distinguished Professor
James Dudley Chair in Lung Cancer Research
Professor, Medical Oncology
University of Colorado Denver
Denver, CO

Paul Bunn, Jr., MD top

Dr. Paul Bunn is arguably one of the most important lung cancer medical oncologist researchers today and among the few experts during the past several decades.

In 1984, Dr. Bunn was recruited to the University of Colorado Health Sciences Center as a Professor of Medicine in Medical Oncology and Head of the Division of Medical Oncology. In 1986 Dr. Bunn became the Director of the University of Colorado Comprehensive Cancer Center.

Dr. Bunn has also been President of the American Society of Clinical Oncology the leading cancer organization of oncology professionals in the world. The network of the American Society of Clinical Oncology comprises nearly 40,000 oncology professionals, about one-third being from more than 100 countries outside of the USA. This organization is dedicated to providing the highest-quality resources in education, policy, clinical research, and in advancing care for patients with cancer. The results of clinical trials presented at its annual meeting are a benchmark of year-to-year progress in the fight against cancer. ASCO’s flagship publication, the Journal of Clinical Oncology (JCO), is an authoritative resource for cancer research findings.

Dr. Bunn has also been the President and Executive Director of the International Association for the Study of Lung Cancer (IASLC) where he held both positions for almost 20 years, until 2013. Under his leadership Dr. Bunn built the IASLC to become the world’s largest association of oncologists, pathologists and healthcare professionals in lung cancer.

Dr. Bunn has also been the President of the Association of American Cancer Institutes (AACI) and has served on the prestigious FDA Oncology Drug Advisory Committee (ODAC) as its chairman.

He is the Chair or Co-Chair of numerous ongoing educational symposia and scientific, clinical and translational research meetings in lung cancer, including the Annual Targeted Therapies for Lung Cancer Meeting now in its seventeenth year held annually in Santa Monica, CA, the Annual Personalized Therapies and Best Clinical Practices for Lung Cancer now in its 9th year, held each year in October in San Francisco, and many others.

Dr. Bunn’s research interests focus on novel therapies for lung cancer. He has published more than 300 articles in peer-reviewed journals, over 122 reviews and editorials, and 90 book chapters on lung cancer. Dr. Bunn’s studies have set standards for the treatment of lung cancer, have identified issues of natural history and have identified biomarkers of prognosis and therapy selection. Dr. Bunn is the principal investigator on numerous national and local therapeutic trials and is also the principal investigator for the SPORE grant in lung cancer that is designed to conduct translational research in lung cancer.

Toni Choueiri, MD
Associate Professor, Medicine, Harvard Medical School
Attending Physician, Solid Tumor Oncology
Director, Genitourinary (GU) Oncology Disease Center
Director, Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute
Boston, MA

Toni Choueiri, MD top

Dr. Toni K. Choueiri is a medical oncologist at Dana-Farber/Brigham and Women’s Cancer Center where he is Director of the Kidney Cancer Center and Clinical Director of the Lank Center for Genitourinary Oncology. Dr. Choueiri has a joint appointment at Harvard Medical School as an Associate Professor of Medicine. He is Co-Leader of the Kidney Cancer Program at Dana-Farber/Harvard Cancer Center and President of the Medical Staff at Dana-Farber. He serves on the NCCN Kidney & Testicular Cancers Panel and is Chairman of the Medical and Scientific Steering Committee of the Kidney Cancer Association.

Dr. Choueiri is interested in developing novel therapies and biomarkers in genitourinary malignancies and renal cell carcinoma. His research focuses on patterns and outcomes of urinary cancers, using a large scale approaches such as meta-analyses from available published trials or national databases such as the SEER database. His work is funded by the American Society of Clinical Oncology, the Harvard Kidney Cancer SPORE and the National Cancer Institute. He has over 300 peer-reviewed publications and is the overall principal investigator of multiple phase I-III trials in genitourinary cancers.

Keith Flaherty, MD
Director, Henri and Belinda Termeer Center for Targeted Therapies
Massachusetts General Hospital Cancer Center
Boston, MA

Keith Flaherty, MD top

Dr. Keith T. Flaherty, M.D., serves as an Associate Professor of Medicine at Harvard Medical School, Associate Physician of Medicine, Hematology/Oncology at Massachusetts General Hospital. Dr. Flaherty is the Co-founder of X4. He has served as a Director of the Henri and Belinda Termeer Center for Targeted Therapies at Massachusetts General Hospital Cancer Center since 2012 Director of Clinical Research at the Massachusetts General Hospital since 2014. Dr. Flaherty is a Clinical Oncologist. He serves as a Senior Editor for Clinical Cancer Research. He has been the Principal Investigator of many clinical trials, including first-in-human trials of novel targeted therapies and two NCI cooperative group trials. He has been the Chairman of the Scientific Advisory Board and Director at Loxo Oncology, Inc. since October 3, 2013 and September 2013 respectively. Dr. Flaherty is the Chair of the Developmental Therapeutics Committee for the Eastern Cooperative Oncology Group (ECOG) and in 2013, was appointed as its Deputy Chair for is a Collaborator and has been a Member of Scientific Advisory Board at Kinagen, Inc. since May 2010. He has been a Member of Scientific Advisory Board at Viralytics Limited since November 2013. He has been a Member of Corporate Advisory Board at X4 Pharmaceuticals Inc. since April 4, 2016. He serves as Member of Oncology Scientific Advisory Board at Asana BioSciences, LLC. He has been Member of Scientific Advisory Board at Aeglea Biotherapeutics, Inc. since September 2016. He serves as a Member of Oncology Advisory Board at Tioma Therapeutics, Inc. He serves as a Member of Scientific Advisory Board at Raze Therapeutics, Inc., Exosome Diagnostics, Inc. and Oncoceutics, Inc. He served as a Member of Scientific Advisory Board at CollabRx, Inc. He serves as a Member of the editorial boards for Cancer Discovery, Journal of Clinical Oncology, Cancer and Pigment Cell and Melanoma Biology. He has authored more than 150 research articles, abstracts and reviews in the peer-reviewed literature, including 3 first-author New England Journal of Medicine papers. He completed his Internship in Medicine, followed by a Residency in Medicine, at Brigham and Women’s Hospital (Harvard Medical School) in Boston. He went on to complete a Fellowship in Medical Oncology at the Hospital of the University of Pennsylvania. Dr. Flaherty has a Bachelor of Science from Yale University in 1993 and an M.D. from Johns Hopkins University in 1997.

Omid Hamid, MD
The Angeles Clinic & Research Institute
Chief of Research/ Immuno-Oncology, The Angeles Clinic
Co-Director, Cutaneous Malignancy Program – Cedars Sinai
Los Angeles, CA

Omid Hamid, MD top

As the Director of the Melanoma Center and Phase I Immuno-Oncology Progrma at The Angeles Clinic and Research Institute, Dr. Omid Hamid works to ensure that patients receive access to the most up-to-date therapeutics, whether . Most recently, in his role with the Phase 1 Developmental Therapeutics Program, Dr. Hamid has been instrumental in bringing new therapies from the investigational lab to the clinic for patient benefit. These therapies involve immunological therapies such as PD-1 inhibitors (Keytruda, Nivolumab, Atezolizumab), therapies against tumor angiogenesis, and targeted agents that block internal processes in tumor cell’s function. These pathways change a normal cell into a cancerous one. Dr. Hamid’s research focus involves manipulation of a patient's immune system to attack cancer cells and maintain continuously elevated levels of immunity and discovery of novel therapies for melanoma.

Dr. Hamid is recognized as a key opinion leader in Immuno-Oncology Drug Development and Melanoma therapeutics and treatment nationally and internationally. Through his role as the Chief of Immunotherapy and Translational Research patients at The Angeles Clinic have benefited from first in class, paradigm shifting drugs. Dr. Hamid was an investigator in the initial trials with Ipilimumab, Pembrolizuma, Nivolumab, Atazolizumab and Vemurafenib, agents that led to significant survival benefits in the lives of our patients. Through his leadership the next phase of agents have been available to our patients. He has been a key investigator on combinations of BRAF/MEK inhibitors and novel immune therapy with PD-1 antibodies making them available for our patients. His curent work focuses on Next-Generation Checkpoint Inhibitors including anti-OX40, 41BB, GITR antibodies. Current work had focused on bringing T-cell adoptive therapies and bispecific antibodies to our program.

Dr Hamid has presented research done at The Angeles Clinic at major national and international meetings including the American Society of Clinical Oncology, Society for Melanoma Research, and many other key national and international meetings. He has published manuscripts, abstracts, and reviews on immunotherpy, targeted therapy, and melanoma care in prestigous journals such as the Journal of Clinical Oncology (JCO), New England Journal of Medicine (NEJM), Clinical Cancer Research.

Dr. Hamid realizes that true benefit rests on fostering innovative therapies directly to the clinical trial format, the most effective a quickest way to ensure patients can benefit through therapy. Through his role as the Chief of Clinical Research, Dr. Hamid oversees a program that ensures all types and stages of melanoma patients have opportunity to benefit from therapy.

Dr. Hamid's clinic research focus includes:

  • Biomarker research
  • Combination therapy for Melanoma
  • Phase I therapeutics
  • Brain metastasis and tumors

Stephen Madison
President and CEO
Oncology Learning Center, Inc., and the
BioMedical Learning Institute
Plano, TX

Stephen Madison top

Steve Madison has been involved with the science and business of oncology/hematology since 1983. He started his career in the field of oncology and hematology as an oncology pharmacist, employed as a pharmaceutical industry marketing executive of Bristol-Myers (BM) for the BM oncology products starting in 1983 as one of only two international marketing executives within BM. In 1983, there were only three cancer pharmaceutical companies in the USA: Bristol-Myers (BM), Mead Johnson and Adria Laboratories. Steve was fortunate to have started establishing working relationships with the academic (“KOL”) leaders in oncology and hematology at the beginning of the oncology business era, 36 years ago. And to this day in 2016, Steve has maintained his important KOL relationships beginning with his employment at Bristol-Myers, but also through his subsequent cancer education and medical advertising companies as described below.

In 1994 Steve left Bristol-Myers and founded and operated, SG Madison & Associates, a global medical/marketing communications and advertising company, which as agency of record, helped successfully launch gemcitabine, trastuzumab, rituximab, cetuximab, and several other oncology and HIV products; but primarily Steve and his medical/marketing company supported the oncology & HIV franchises of Bristol-Myers (eventually Bristol-Myers Squibb) in the US and Globally, plus the businesses of ImClone, Genentech, Lilly and several other companies not on a retainer basis.

In 1999 Steve founded the first of his two CME/CE accredited companies: the CBCE (Center for Biomedical Continuing Education) which he sold in 2001 along with his medical/marketing communications agency, SG Madison & Associates. During his tenure at his two CME/CE companies and SG Madison & Associates, Steve founded several major ongoing cancer education meetings and symposia, and at least two of which are still ongoing today, including the now 17th Annual Anti-Angiogenic Symposium held each year in La Jolla, CA, sponsored by MD Anderson Cancer Center and co-chaired by Dr. George Sledge and Lee Ellis, the now 17th Annual Targeted Therapies for Lung Cancer Meeting, held each year in Santa Monica, CA, sponsored by the IASLC co-chaired by Drs. Paul Bunn, Roy Herbst, Dave Johnson and Fred Hirsch.

In 2006 Steve founded the Oncology Learning Center, Inc., (also operated as the BioMedical Learning Institute) which conducts numerous live and Web-based oncology/hematology educational CME/CE activities, including annual satellite CME/CE symposia at the annual meetings of the American Society of Clinical Oncology, the American Society of Hematology, the San Antonio Breast Cancer Symposium, the Oncology Nursing Society and many other meetings and congresses, and including of its own, stand-alone educational events (of the BLMI) including the annual Symposium on Personalized Therapies and Best Clinical Practices for lung Cancer now in its 9th consecutive year, and its 1st Annual Symposium on Integrating Immune Therapy and Targeted Therapy into Standards of Care for Hematologic and Solid Malignancies to be held on September 10, 2016 in San Francisco.

In addition, Steve and the Oncology Learning Center have now resumed the highly successful Cancer Master Classes that were suspended in 2005, beginning with the October 19-21, 2016 Strategic Cancer Business Master Class and Other Master Classes will follow shortly. Please see: www.OncologyLearningCenter.com

Finally, Steve owns but does not (presently) operate several other cancer businesses of importance to pharmaceutical and diagnostic/laboratory companies, including his cancer consulting company, Steve Madison Cancer Consulting, as well as his oncology KOL development company: InsiderMD.com; his customized oncology training company: CPLS.com (Customized Pharmaceutical Learning Systems), and also his customized cancer market research company: Oncology Insights.com. The reason for Steve’s lack of involvement (for the present), is the 2009 legislation prohibiting his participation in both CME and non CME companies. It is anticipated that this will change in the very near future as Steve his other executives to operate his CME business, thus enabling Steve to operate freely inside his non-CME businesses: InsiderMD.com, CPLS.com (Customized Pharmaceutical Learning Systems), Steve Madison Consulting.com and Oncology Insights.com. Should anyone be interested in any of these business or their services please contact Steve.Madison@CPLS.com.

Eileen O'Reilly, MD
Associate Director,
David M. Rubenstein Center for
Pancreatic Cancer Research
Memorial Sloan Kettering Cancer Center
New York, NY

Eileen O'Reilly, MDtop

Dr. Eileen M. O’Reilly is an Associate Member of the in the GI Medical Oncology service at Memorial Sloan-Kettering Cancer Center (MSKCC) in New York and an Associate Professor of Medicine at Weill Medical College of Cornell University. Dr. O’Reilly received her medical degree at Trinity College (Dublin University) in Ireland, where she was born. She completed her residency training in Ireland and Fellowship training at MSKCC and has been a faculty member in the GI Oncology service at MSKCC since that time. Dr. O’Reilly has pancreatic and hepatobiliary malignancies as the major focus of her research and clinical activities. Research initiatives include integration of molecular-based therapies for the treatment of pancreas cancer along with development of adjuvant and neoadjuvant therapies and identification of biomarkers that maybe used to select therapy. Dr. O’Reilly is the Chair of the NCI Pancreas Task Force, member of the Alliance GI core committee, member of the Advisory Board of the Lustgarten Foundation Pancreas Research Consortium and of the Medical Advisory Board of the Pancreatic Cancer Action Network and ASCO IMT committee. Dr. O’Reilly teaches and mentors medical oncology fellows (national and international), junior faculty, residents and house-staff and has numerous teaching awards. Dr. O’Reilly’s institutional administrative commitments include Associate Chairpersonship of MSKCC’s Institutional Review & Privacy Board (IRB), and membership of the Research Council and Clinical Council. Dr. O’Reilly is the recent Past-President of the MSKCC Medical Staff.

Robert Orlowski, MD, PhD
Department Chair ad interim, Department of Lymphoma/Myeloma
Professor, Department of Lymphoma/Myeloma
Florence Maude Thomas Cancer Research Professorship, Department of Lymphoma/Myeloma
The University of Texas MD Anderson Cancer Center
Houston, TX

Robert Orlowski, MD, PhDtop

Bio Statement

Robert Z. Orlowski, MD, PhD, is Chairman, Ad Interim, Director of Myeloma, and Professor of Medicine in the Departments of Lymphoma/Myeloma and Professor, Experimental Therapeutics, Division of Cancer Medicine, at The University of Texas M.D. Anderson Cancer Center in Houston, Texas. He is board-certified in internal medicine and medical oncology. Dr. Orlowski earned his doctoral degree in molecular biophysics and biochemistry from Yale University and his medical degree from the Yale University School of Medicine. He completed his internship and residency in Internal Medicine at Barnes Hospital at the Washington University in St. Louis School of Medicine. Dr. Orlowski has published numerous book chapters, articles, and abstracts on cancer therapy, with a focus on the molecular pathogenesis of oncologic disease processes and the mechanisms of action of chemotherapeutics.

Research Interests

His clinical research efforts focus on the translation of promising laboratory based findings into novel clinical trials for patients with hematologic malignancies. He has published in, and is a reviewer for, several journals, including Blood, Cancer Research, Journal of Clinical Oncology, and the New England Journal of Medicine. He has received several awards, including The Leukemia & Lymphoma Society Scholar in Clinical Research and the Jefferson-Pilot Fellowship in Academic Medicine.

John Pagel, MD, PhD, DSc
Chief of Hematologic Malignancies Program
Director, Stem Cell Transplantation
Swedish Cancer Institute
Seattle, WA

John Pagel, MD, PhD, DSctop

John M Pagel, MD, PhD, is Affiliate Associate Member in the Department of Medicine, Division of Oncology at the University of Washington and Chief of Hematologic Malignancies Program at the Swedish Cancer Institute. He earned his Medical Degree from Boston University School of Medicine in Boston, Massachusetts, where he graduated magna cum laude, and his Doctor of Philosophy in Microbiology and Molecular Genetics from the University of California in Irvine, CA. Prior to his current position as Research Associate, he was a senior fellow at Fred Hutchinson Cancer Research Center. Dr. Pagel has received numerous awards, including the ASCO Young Investigator Award, Lymphoma Research Foundation Career Development Award, ASCO Career Development Award, University of California President's Award, and a Howard Hughes Post-Doctoral Research Award. In addition, he is a member of several professional societies, including the American Association of Cancer Research, American Society of Hematology, and the American Association of Clinical Oncology. Throughout his career, Dr. Pagel has published many abstracts and articles in a variety of publications

Daniel Petrylak, MD
Professor of Medicine, Medical Oncology and Urology
Professor & Co-Director
Signal Transduction Research Program
Yale Comprehensive Cancer Center
Yale School of Medicine
New Haven, CT

Daniel Petrylak, MD top

As Professor of Medicine and Urology at Yale School of Medicine, Dr. Daniel P. Petrylak is a pioneer in the research and development of new drugs and treatments to fight prostate, bladder, kidney and testicular cancer. For patients fighting these types of cancers, Petrylak finds recent developments in the field of immunotherapy particularly promising. “Up until recently, bladder cancer had not seen any major advancement in more than 30 years,” he says. “Studies are ongoing, but interim results are exciting so far.”

At the Smilow Cancer Hospital, Dr. Petrylak’s position as a national leader on clinical trials for men with prostate and bladder cancer has opened up a world of treatment options for patients in New England. “We offer the latest investigational drugs for these conditions, while providing the highest level of care,” he says.

Dr. Petrylak received his MD from Case Western Reserve University School of Medicine and joined the Yale faculty in 2012. In addition to his role as professor, he is also the co-director of the Signal Transduction Research Program at Yale Cancer Center, which studies how cancer stem cells are regulated in the body and communicate with surrounding tissue. Roughly 40 physicians and scientists in the program work together to develop the best methods for matching patients with the appropriate cancer drugs.

One of Dr. Petrylak’s key goals is to continue to successfully translate basic research into clinical practice. “One of the most significant accomplishments in my career was moving docetaxel (an antineoplastic agent) therapy for the most advanced form of prostate cancer from phase I to III,” he says. “We ran a trial which supported its approval for the most advanced form of prostate cancer.”

Dr. Petrylak currently serves as either the principal investigator or co-principal investigator on seven Southwest Oncology Group (SWOG) clinical trials for genitourinary cancers. To date, he has authored more than 100 peer-reviewed articles on prostate and bladder cancer research.

Stanley Riddell, MD
Professor, School of Medicine
University of Washington
Seattle Cancer Care Alliance
Seattle, WA

Stanley Riddell, MDtop

Prof. Stanley R. Riddell, also known as Stan, MD, is Scientific Co-Founder of Juno Therapeutics Inc. Prof. Riddell is a member of the Clinical Research Division at Fred Hutchinson Cancer Research Center and Professor of Oncology at the University of Washington School of Medicine. Dr. Riddell is a leader in developing therapies that harness the immune system to fight cancer and infectious diseases. His research led to patented technologies that rapidly expand the number of disease fighting T cells used in adoptive immunotherapy. He also isolated a rare subset of disease-fighting T cells that survive in patients for an extraordinary amount of time. He joined FHCRC Faculty in 1991 after training in medical oncology and immunology. Dr. Riddell was elected to the Association of American Physicians, an organization honoring those who have achieved excellence in biomedical science. He served as an Associate Professor of University of Washington School of Medicine, since 2000. Mr. Riddell serves as a Member of Scientific Advisory Board of Cellerant Therapeutics Inc. He serves as Member of Scientific Advisory Team of Cell Medica Limited. He is a Member of the American Association for the Advancement of Science, the American Society of Gene Therapy, and the American Society of Hematology. He is the recipient of ASCO Young Investigator Award and the Cancer Research Institute Partridge Foundation Investigator Award. In 2010, Dr. Riddell received the International Society for Biological Therapy of Cancer’s first Team Science Award for major contributions to research and the clinical translation of cancer immunotherapy. Mr. Riddell earned his M.D. at University of Manitoba and is a Board Certified Medical Oncologist.

Susan Slovin, MD, PhD
Attending Physician, Member
Genitourinary Oncology Service
Sidney Kimmel Center for Prostate and Urologic Cancers
Memorial Sloan Kettering Cancer Center
Professor of Medicine
Weill Cornell Medical College
New York, NY

Susan Slovin, MD, PhD top

Clinical Expertise: Prostate Cancer; Clinical Immunology; Other Genitourinary Malignancies
Education: MD, Jefferson Medical College; PhD, Columbia University Graduate School of Arts and Sciences
Residencies: Mount Sinai Medical Center (New York)
Fellowships: Memorial Sloan Kettering Cancer Center
Board Certifications: Internal Medicine; Medical Oncology

Click here for a list of publications.

Clinical Trials Led by Susan F. Slovin

  • A Phase Ib Study of Enzalutamide plus Ribociclib in Men with Advanced Prostate Cancer
  • A Phase II Study of Abiraterone with or without Cabazitaxel in Patients with Metastatic Castration-Resistant Prostate Cancer
  • A Study Comparing the Cardiovascular Safety of Degarelix versus Leuprolide in Men with Cardiovascular Disease Receiving Hormonal Therapy for Advanced Prostate Cancer
  • Adoptive Transfer of Autologous T Cells Targeted to Prostate-Specific Membrane Antigen for the Treatment of Metastatic Castration-Resistant Prostate Cancer
Clinical Trials Co-Investigated by Susan F. Slovin
  • A Phase I Study of a Vaccine-Based Immunotherapy (PrCa VBIR) for Prostate Cancer

David Spigel, MD
Director, Lung Cancer Research Program
Sarah Cannon Research Institute
Tennessee Oncology
Nashville, TN

David Spigel, MD top

Dr. Spigel joined Sarah Cannon in 2003 and as chief scientific officer, he oversees all scientific aspects of Sarah Cannon's clinical trial program, working with the research physician leaders to ensure the best new agents and studies are available to our patients. He serves as a primary contact for the Pharma and biotech partners as well as the strategic site physicians with whom Sarah Cannon conducts cancer research.

Dr. Spigel received his bachelor’s degree from Tulane University in New Orleans in 1992, and medical degree from The University of Tennessee in Memphis in 1996. After completing an internal medicine and chief residency at Indiana University Medical Center, he completed a fellowship in hematology and oncology at The Dana-Farber Cancer Institute in Boston. He is board certified in medical oncology. Additionally, he is an associate with Tennessee Oncology, PLLC.

Mario Sznol, MD
Professor of Medicine
Yale University School of Medicine
Co-Director, Yale SPORE in Skin Cancer
Yale Comprehensive Cancer Center
New Haven, CT

Mario Sznol, MD top

Dr. Mario Sznol, M.D., served as Vice President of Clinical Affairs at Vion Pharmaceuticals Inc. from September 1999 to October 15, 2004. From 1987 to 1999, Dr. Sznol worked for the National Cancer Institute, or NCI, an institute of the National Institutes of Health. He served as Head of the Biologics Evaluation Section, Investigational Drug Branch, Cancer Therapy Evaluation Program from 1994 to 1999. From March 1997 to October 1998, he served as an Acting Chief of NCI's Investigational Drug Branch, Cancer Therapy Evaluation Program. He serves as a Member of Scientific Advisory Board at Lion Biotechnologies, Inc. He has been a Member of Scientific Advisory Board at Intensity Therapeutics, Inc. since October 22, 2015. He serves as a Member of Scientific Advisors at Anaeropharma Science, Inc. He serves as a Member of Scientific Advisory Board at Symphogen A/S. He has been a Member of Scientific Advisory Board at Lycera Corp. since November 10, 2016. He served as a Director of Vion Pharmaceuticals Inc. since October 15, 2004. He is a Professor of Internal Medicine, Co-Director of the Melanoma Program and Co-Director of Yale SPORE in Skin Cancer at Yale University School of Medicine. He is an investigator in several clinical trials at the Yale Cancer Center, including those focusing on immunotherapy and novel agents. He spent the next twelve years in the Biologics Evaluation Section (BES), Investigational Drug Branch of the Cancer Therapy Evaluation Program at the National Cancer Institute (NCI). Dr. Sznol has an international reputation in cancer drug development with expertise in cancer immunotherapy and the treatment of patients with melanoma and renal cell carcinoma. He conducted his fellowship in Medical Oncology, Department of Neoplastic Diseases, at Mt. Sinai School of Medicine and his residency in Internal Medicine at Baylor College of Medicine in Houston. Dr. Sznol received his BA from Rice University and an MD from the Baylor College of Medicine and Yale University School Of Medicine. He trained in internal medicine.

Anne Tsao, MD
Associate Professor
Department of Thoracic/Head and Neck Medical Oncology
Division of Cancer Medicine
Director, Mesothelioma Program
Director, Thoracic Chemo-Radiation Program
The University of Texas MD Anderson Cancer Center
Houston, TX

Anne Tsao, MD top

As director of the mesothelioma program at the M.D. Anderson Cancer Center at the University of Texas in Houston, Anne Tsao M.D. is one of the nation's foremost authorities on malignant mesothelioma.

Educational Background
Tsao earned her medical degree from the prestigious University of Chicago Pritzker School of Medicine. She completed her internship and residency at Indiana University in Indiana and an additional residency at the University of Texas. Before joining the staff at M.D. Anderson, she also completed a fellowship at the facility. Board certified in both internal medicine and medical oncology, Dr. Tsao specializes in thoracic, head, and neck oncology and serves as director of the Mesothelioma Program at the hospital.

Professional Highlights and Publications
Dr. Tsao and her colleagues at Anderson have penned many articles providing a large amount of information for many professional journals and have been involved in numerous clinical trials involving the treatment of malignant mesothelioma, an aggressive form of cancer that is often diagnosed in advanced stages and difficult to treat.

In articles in publications such as the Journal of Clinical Oncology, Tsao has discussed the impact of novel therapies, the importance of clinical trials, and controversial issues such as the use of extrapleural pneumonectomy in the treatment of the disease. She has also campaigned for the use of intrapleural therapies as well as gene therapy and immunotherapy for the treatment of malignant pleural mesothelioma and lectures nationally and internationally on these subjects.

Clinical Research
Tsao has also performed studies involving smoking history and its impact on the prognosis of those with non-small cell lung cancers like mesothelioma. She has also stressed the need for chemo-prevention, the use of natural, synthetic, or biologic chemical agents to suppress cancer in high-risk populations or prevent carcinogenic progression to invasive cancer.

Awards and Affiliations
For her work in the field of thoracic and other cancers, Dr. Tsao has been the recipient of numerous awards including an ASCO (American Society of Clinical Oncology) Merit Award, M.D. Anderson Achievement in Research Award, ASCO Young Investigator Award, ASCO Career Development Award, NIH Clinician Scientist K12 Award, and Head and Neck SPORE Career Development Award. Tsao also serves on the Southwest Oncology Steering Committee and is a member of the Scientific Board of the American Radium Society.

Jeffrey Weber, MD, PhD
Deputy Director, Laura & Isaac Perlmutter Cancer Center
Co-Director, Melanoma Program
Head of Experimental Therapeutics
NYU Langone NCI Comprehensive Cancer Center
New York, NY

Jeffrey Weber, MD, PhD top

Dr. Weber earned his Ph.D. in molecular cell biology from Rockefeller University (New York) in 1979 and received his M.D. from New York University in 1980. He completed his internship and residency in Medicine at the University of California, San Diego, and his fellowship in Medical Oncology at the National Cancer Institute in Bethesda, MD.

His experience includes clinical, research and teaching positions at the University of California, Irvine, and the University of Southern California where he was Chief of Medical Oncology and Associate Director for Clinical Research at the USC/Norris Comprehensive Cancer Center. Coming to Moffitt in 2007, Dr. Weber is a Senior Member, Director of the Donald A. Adam Comprehensive Melanoma Research Center, and Professor in the Department of Oncologic Sciences.

A specialist in cancer immunotherapy, Dr. Weber is principal investigator (PI) on several ongoing studies funded by the National Cancer Institute (NCI), including trials in clinical drug development, vaccines, and studies on autoimmunity and melanoma. He has been continuously NCI R01 funded for the last 16 years. Dr. Weber is also the Principal Investigator and Director of the Moffitt Skin Cancer SPORE (P50) NCI grant, a collaborative, multi-project translational research program. Dr. Weber has published more than 100 articles in the top peer-reviewed journals in his field including New England Journal of Medicine, Clinical Cancer Research, Journal of Clinical Oncology and Nature Medicine. Dr. Weber sat on the National Cancer Institute’s Clinical Oncology Study section as well as the boards of the Melanoma Research Foundation and the Melanoma Therapeutics Foundation, and served as a chair of the Veterans Administration’s clinical oncology study section. He currently sits on the scientific advisory boards of four cancer-related biotechnology companies.

Dr. Weber’s research interests are in the field of immunotherapy for cancer. As a translational clinical investigator, Dr. Weber has performed a variety of vaccine trials, protocols involving adoptive cell therapy, and novel immunotherapy trials in melanoma patients. His specific laboratory interests are in the monitoring and characterization of T cell responses in patients with cancer, and the establishment of in vitro models to facilitate the understanding of how immune modulation via abrogating and activating antibodies amplifies adaptive immunity in patients. Clinically, he has held 10 investigator-initiated IND over the last decade, and has pursued cutting edge trials recently using gene modified dendritic cells, intranodal injection of plasmid-peptide priming and boosting and novel antibodies like CTLA-4 and PD-1 abrogating antibodies. He has been a pioneer in the clinical advancement of antibodies that induce autoimmunity as a surrogate for clinical benefit in cancer, and the management of the autoimmune side effects.

Jared Weiss, MD
Assistant Professor
Division of Hematology and Oncology
School of Medicine
Clinical Research
Thoracic Oncology Program
University of North Carolina
Chapel Hill, NC

Jared Weiss, MD top

Clinically, Dr. Weiss is focused on treating patients with lung cancer and head and neck cancers. Dr. Weiss’ research is focused on clinical trials in lung cancer and head/neck cancer. Dr. Weiss serves as section chief of thoracic and head/neck oncology and research POD leader for thoracic oncology. Dr. Weiss serves as associate director for finance of the Clinical Protocol Office. He also serves as the vice president of cancergrace.org, a global resource with the goal of increasing patient education and family information on cancer and is an advocate and board member of the Lung Cancer Initiative of North Carolina.

Dr. Jared Weiss is a medical oncologist in Chapel Hill, North Carolina. He received his medical degree from Yale University School of Medicine and has been in practice between 11-20 years.

H. Jack West, MD
Medical Director, Thoracic Oncology Program
Swedish Cancer Institute
President and CEO
Global Resource for Advancing Cancer Education
Seattle, WA

H. Jack West, MD top

Dr. West received an MPhil in Experimental Biology from Cambridge University on a Fulbright Scholarship and a medical degree (magna cum laude) from Harvard Medical School, where Dr. West also conducted research as a Howard Hughes Medical Student Fellow. His postdoctoral training included an internship and residency in internal medicine at the Harvard-affiliated Brigham and Women’s Hospital Boston, MA, followed by a fellowship in medical oncology at the Fred Hutchinson Cancer Research Center/ University of Washington in Seattle, WA. He joined Swedish Cancer Institute in late 2002 as a medical oncologist and lung cancer specialist. He also serves as Medical Director of the Thoracic Oncology Program and has a significant clinical interest as well in genitourinary oncology.

Dr. West has published numerous articles in peer-reviewed literature and has authored several book chapters. He also now serves as the Web Editor of JAMA Oncology and is on the editorial boards of Journal of Clinical Oncology, Journal of Medicine, Clinical Lung Cancer, and Journal of Thoracic Disease, in addition to serving as an author of multiple lung cancer-related sections of Up-To-Date and as a reviewer for more than a dozen professional journals. Dr. West leads a wide range of clinical trials and has been actively involved with the SWOG Lung Cancer Committee as a Study Coordinator/Principal Investigator.

Dr. West founded and continues to serve as President of the nonprofit organization Global Resource for Advancing Cancer Education (GRACE), a source of timely, free information for patients and caregivers dealing with cancer that currently receives over 50 thousand visits per month from over 100 countries around the world.

Dr. West is also working to develop telemedicine-based practice patterns to broaden the range of treatment options for cancer patients and serves as the Chair of the Outreach/Education/Telemedicine Working Group for the Cancer Clinical Provider Group as part of the Providence/Swedish Hospital Network. He is also a regular session chair on numerous annual lung cancer an immune and targeted therapy CME symposia such as the Annual Personalized Therapies and Best Clinical Practices Symposia each year in October in San Francisco. He is often a co-chair of satellite educational symposia on lung cancer at the annual meeting of the American Society of Clinical Oncology in Chicago in May and June.

Anas Younes, MD
Chief, Lymphoma Service
Memorial Sloan-Kettering Cancer Center
New York, NY

Anas Younes, MD top

As a medical oncologist and Chief of Memorial Sloan Kettering’s Lymphoma Service, Anas Younes works with his clinical and basic-science colleagues to accelerate the translation of recent scientific discoveries into novel treatment strategies to improve the cure rate and survival of patients with Hodgkin and non-Hodgkin lymphoma.

Anas Younes joined Memorial Sloan Kettering in 2013 with two decades of experience in treating and managing people with lymphoma, and with an extensive background in translational scientific research. Anas Younes is particularly interested in developing novel targeted therapies and linking them to biomarkers (early markers) that can help match patients with the most effective and minimally toxic medicines.

Anas Younes have served as the principal investigator of more than 60 clinical trials in patients with Hodgkin and non-Hodgkin lymphoma, including national and international multi-center studies. Anas Younes has led the efforts of developing the first FDA-approved targeted drug for the treatment of Hodgkin lymphoma in more than three decades (Brentuximab vedotin).

Nationally, Anas Younes has led a National Cancer Institute-funded Specialized Programs of Research Excellence (SPOREs) in lymphoma focused on developing novel treatment strategies for Hodgkin and non-Hodgkin lymphoma. Anas Younes also serves on the Scientific Advisory Board of the Lymphoma Research Foundation, and is a member of the National Cancer Institute Lymphoma Steering Committee.

Anas Younes actively posts on social media about clinical trials, news stories, scientific publications, and medical advances.

  • Clinical Expertise: Hodgkin and Non-Hodgkin Lymphomas; New Targeted Therapies
  • Education: MD, The University of Damascus School of Medicine (Damascus, Syria)
  • Residencies: Medical College of Ohio (Toledo, Ohio); SUNY Downstate Medical Center (Brooklyn, NY)
  • Fellowships: Memorial Sloan Kettering Cancer Center
  • Board Certifications: Internal Medicine; Medical Oncology

© 2019 Oncology Learning Center, Inc.